Company news

Capricor Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7

July 30, 2024

Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

June 30, 2024

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy

June 27, 2024

CORRECTION: Capricor Therapeutics

June 24, 2024

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

June 24, 2024

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway

June 10, 2024

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

June 3, 2024

Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 12, 2024

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

May 8, 2024

Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences

May 7, 2024

Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13

May 5, 2024

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

April 23, 2024

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

March 5, 2024

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 28, 2024

Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

February 26, 2024

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

February 21, 2024

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

February 19, 2024

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

January 23, 2024

Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

December 10, 2023

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 13, 2023

Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14

November 6, 2023

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program

October 18, 2023

Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

October 9, 2023

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

September 28, 2023

Capricor Therapeutics Announces $23 Million Registered Direct Offering

September 28, 2023

Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

September 5, 2023

Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 6, 2023

Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7

August 1, 2023

Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors

July 23, 2023

Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

July 12, 2023

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

June 29, 2023

Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

June 12, 2023

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

June 6, 2023

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 10, 2023

Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11

May 3, 2023

Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform

April 26, 2023

Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

March 22, 2023

Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 14, 2023

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan

February 15, 2023

Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients

January 24, 2023

Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform

January 11, 2023

Capricor Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 9, 2022

Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 9, 2022

Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

July 18, 2022

Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study

June 26, 2022

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

May 24, 2022

Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022

Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients

March 27, 2022

Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 9, 2022

Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10

March 2, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 38 decks. Every deck is listed under its year.